beyond her2: dissecting tumor heterogeneity
Published 4 years ago • 197 plays • Length 6:15Download video MP4
Download video MP3
Similar videos
-
2:20
peace and tracerx: dissecting metastases and intra-tumor heterogeneity
-
10:07
importance of biomarkers when evaluating heterogeneity in her2 metastatic bc
-
1:22
investigating tumor heterogeneity in the tracerx study
-
0:31
remaining questions regarding her2-low breast cancer
-
1:45
the comprehensive genomic characterization of her2-low breast cancer
-
3:18
molecular heterogeneity in her2 breast cancer and predicting outcomes
-
0:42
treating her2-positive solid tumors with tac t-cell therapy
-
2:14
clinical and molecular characteristics of her2-low/zero early stage triple-negative breast cancer
-
1:25
her2-low as a separate entity for defining her2 bc and its prognostic and biological significance
-
1:05
the genomic characterization of primary and metastatic her2-low breast cancers
-
1:00
utilizing neoadjuvant immunotherapies in patients with er , her2- primary breast cancer
-
0:56
gut microbiome and treatment outcomes in hr /her2- breast cancer
-
2:49
her2-e pcr with anti-her2-based neoadjuvant therapies
-
1:26
genomic and transcriptomic landscape of her2-low breast cancer
-
5:03
challenges in classifying bladder tumors: insights on heterogeneity and precision
-
3:06
prognostic score in early hr /her2- breast cancer: rs, factors, mutations, histology
-
5:55
decision-making in metastatic her2 breast cancer
-
1:49
anti-her2 car macrophages for solid tumors
-
2:19
her2 heterogeneity and neoadjuvant therapy in breast cancer